Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

N-Oxygenation of Oxycodone and Retro-reduction of Oxycodone N-Oxide.

Cashman JR, Gohdes M, de Kater A, Schoenhard G.

Drug Metab Dispos. 2019 Nov 14. pii: dmd.119.089300. doi: 10.1124/dmd.119.089300. [Epub ahead of print]

PMID:
31727673
2.

A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.

Cheng J, Moore S, Gomez-Galeno J, Lee DH, Okolotowicz KJ, Cashman JR.

J Pharmacol Exp Ther. 2019 Dec;371(3):703-712. doi: 10.1124/jpet.119.261040. Epub 2019 Oct 3.

3.

Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ.

Hurtado C, Safarova A, Smith M, Chung R, Bruyneel AAN, Gomez-Galeno J, Oswald F, Larson CJ, Cashman JR, Ruiz-Lozano P, Janiak P, Suzuki T, Mercola M.

Sci Rep. 2019 Jul 25;9(1):10811. doi: 10.1038/s41598-019-46948-5.

4.

Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53.

Cheng J, Okolotowicz KJ, Ryan D, Mose E, Lowy AM, Cashman JR.

Am J Cancer Res. 2019 Feb 1;9(2):390-405. eCollection 2019.

5.

Curcumin and Novel Synthetic Analogs in Cell-Based Studies of Alzheimer's Disease.

Gagliardi S, Franco V, Sorrentino S, Zucca S, Pandini C, Rota P, Bernuzzi S, Costa A, Sinforiani E, Pansarasa O, Cashman JR, Cereda C.

Front Pharmacol. 2018 Dec 3;9:1404. doi: 10.3389/fphar.2018.01404. eCollection 2018.

6.

b-Annulated 1,4-dihydropyridines as Notch inhibitors.

Gómez-Galeno JE, Hurtado C, Cheng J, Yardimci C, Mercola M, Cashman JR.

Bioorg Med Chem Lett. 2018 Nov 1;28(20):3363-3367. doi: 10.1016/j.bmcl.2018.09.002. Epub 2018 Sep 5.

7.

Novel tertiary sulfonamides as potent anti-cancer agents.

Okolotowicz KJ, Dwyer M, Ryan D, Cheng J, Cashman EA, Moore S, Mercola M, Cashman JR.

Bioorg Med Chem. 2018 Aug 15;26(15):4441-4451. doi: 10.1016/j.bmc.2018.07.042. Epub 2018 Jul 25.

PMID:
30075999
8.

A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer.

Cheng J, Dwyer M, Okolotowicz KJ, Mercola M, Cashman JR.

Cancer Res. 2018 Sep 1;78(17):5072-5083. doi: 10.1158/0008-5472.CAN-17-2642. Epub 2018 Jul 21.

9.

Use of Hupresin To Capture Red Blood Cell Acetylcholinesterase for Detection of Soman Exposure.

Onder S, Schopfer LM, Cashman JR, Tacal O, Johnson RC, Blake TA, Lockridge O.

Anal Chem. 2018 Jan 2;90(1):974-979. doi: 10.1021/acs.analchem.7b04160. Epub 2017 Dec 13.

10.

An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes.

McKeithan WL, Savchenko A, Yu MS, Cerignoli F, Bruyneel AAN, Price JH, Colas AR, Miller EW, Cashman JR, Mercola M.

Front Physiol. 2017 Oct 11;8:766. doi: 10.3389/fphys.2017.00766. eCollection 2017.

11.

Immunopurification of Acetylcholinesterase from Red Blood Cells for Detection of Nerve Agent Exposure.

Dafferner AJ, Schopfer LM, Xiao G, Cashman JR, Yerramalla U, Johnson RC, Blake TA, Lockridge O.

Chem Res Toxicol. 2017 Oct 16;30(10):1897-1910. doi: 10.1021/acs.chemrestox.7b00209. Epub 2017 Sep 25.

12.

1,5-Disubstituted benzimidazoles that direct cardiomyocyte differentiation from mouse embryonic stem cells.

Okolotowicz KJ, Bushway P, Lanier M, Gilley C, Mercola M, Cashman JR.

Bioorg Med Chem. 2015 Sep 1;23(17):5282-92. doi: 10.1016/j.bmc.2015.07.073. Epub 2015 Aug 4.

13.

Synergistic effect of Wnt modulatory small molecules and an osteoinductive ceramic on C2C12 cell osteogenic differentiation.

Chen S, Ryan DA, Dwyer MA, Cashman JR.

Bone. 2014 Oct;67:109-21. doi: 10.1016/j.bone.2014.06.032. Epub 2014 Jul 3.

PMID:
24998670
14.

Novel human butyrylcholinesterase variants: toward organophosphonate detoxication.

Dwyer M, Javor S, Ryan DA, Smith EM, Wang B, Zhang J, Cashman JR.

Biochemistry. 2014 Jul 15;53(27):4476-87. doi: 10.1021/bi500491w. Epub 2014 Jun 30.

15.

Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ-opioid receptor antagonist.

Cashman JR, Azar MR.

J Pharmacol Exp Ther. 2014 Jul;350(1):171-80. doi: 10.1124/jpet.114.214262. Epub 2014 May 9.

16.

Preclinical studies of noncharged oxime reactivators for organophosphate exposure.

Okolotowicz KJ, Dwyer M, Smith E, Cashman JR.

J Biochem Mol Toxicol. 2014 Jan;28(1):23-31. doi: 10.1002/jbt.21519. Epub 2013 Aug 13.

PMID:
23943350
17.

Mass spectrometry method to identify aging pathways of Sp- and Rp-tabun adducts on human butyrylcholinesterase based on the acid labile P-N bond.

Jiang W, Cashman JR, Nachon F, Masson P, Schopfer LM, Lockridge O.

Toxicol Sci. 2013 Apr;132(2):390-8. doi: 10.1093/toxsci/kft011. Epub 2013 Jan 23.

18.

Immunodetection of serum albumin adducts as biomarkers for organophosphorus exposure.

Chen S, Zhang J, Lumley L, Cashman JR.

J Pharmacol Exp Ther. 2013 Feb;344(2):531-41. doi: 10.1124/jpet.112.201368. Epub 2012 Nov 28.

19.

Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling.

Schade D, Lanier M, Willems E, Okolotowicz K, Bushway P, Wahlquist C, Gilley C, Mercola M, Cashman JR.

J Med Chem. 2012 Nov 26;55(22):9946-57. doi: 10.1021/jm301144g. Epub 2012 Nov 6.

20.

Regulation of FMO and PON detoxication systems in ALS human tissues.

Gagliardi S, Abel K, Bianchi M, Milani P, Bernuzzi S, Corato M, Ceroni M, Cashman JR, Cereda C.

Neurotox Res. 2013 May;23(4):370-7. doi: 10.1007/s12640-012-9356-1. Epub 2012 Oct 17.

PMID:
23073612
21.

Identification of human butyrylcholinesterase organophosphate-resistant variants through a novel mammalian enzyme functional screen.

Zhang J, Chen S, Ralph EC, Dwyer M, Cashman JR.

J Pharmacol Exp Ther. 2012 Dec;343(3):673-82. doi: 10.1124/jpet.112.198499. Epub 2012 Sep 6.

22.

pH dependence on functional activity of human and mouse flavin-containing monooxygenase 5.

Motika MS, Zhang J, Ralph EC, Dwyer MA, Cashman JR.

Biochem Pharmacol. 2012 Apr 1;83(7):962-8. doi: 10.1016/j.bcp.2012.01.006. Epub 2012 Jan 13.

PMID:
22266355
23.

Substituted heteroaromatic compounds: effect on nicotine self-administration in rats.

Cashman JR, Okolotowicz K, Cerny M, Johnson R, Janowsky A, Azar MR.

Psychopharmacology (Berl). 2012 Jun;221(4):637-48. doi: 10.1007/s00213-011-2608-6. Epub 2012 Jan 5.

PMID:
22218454
24.
25.

Genomic and nongenomic signaling induced by 1α,25(OH)2-vitamin D3 promotes the recovery of amyloid-β phagocytosis by Alzheimer's disease macrophages.

Mizwicki MT, Menegaz D, Zhang J, Barrientos-Durán A, Tse S, Cashman JR, Griffin PR, Fiala M.

J Alzheimers Dis. 2012;29(1):51-62. doi: 10.3233/JAD-2012-110560.

PMID:
22207005
26.

Nonquaternary reactivators for organophosphate-inhibited cholinesterases.

Kalisiak J, Ralph EC, Cashman JR.

J Med Chem. 2012 Jan 12;55(1):465-74. doi: 10.1021/jm201364d. Epub 2011 Dec 29.

PMID:
22206546
27.

Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response.

Lanier M, Schade D, Willems E, Tsuda M, Spiering S, Kalisiak J, Mercola M, Cashman JR.

J Med Chem. 2012 Jan 26;55(2):697-708. doi: 10.1021/jm2010223. Epub 2012 Jan 13.

28.

Curcumins promote monocytic gene expression related to β-amyloid and superoxide dismutase clearance.

Cashman JR, Gagliardi S, Lanier M, Ghirmai S, Abel KJ, Fiala M.

Neurodegener Dis. 2012;10(1-4):274-6. doi: 10.1159/000333123. Epub 2011 Dec 7.

PMID:
22156608
29.

Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to β-amyloid clearance.

Gagliardi S, Ghirmai S, Abel KJ, Lanier M, Gardai SJ, Lee C, Cashman JR.

Chem Res Toxicol. 2012 Jan 13;25(1):101-12. doi: 10.1021/tx200246t. Epub 2011 Nov 7.

PMID:
22029407
30.

His-tag truncated butyrylcholinesterase as a useful construct for in vitro characterization of wild-type and variant butyrylcholinesterases.

Ralph EC, Xiang L, Cashman JR, Zhang J.

Protein Expr Purif. 2011 Nov;80(1):22-7. doi: 10.1016/j.pep.2011.07.005. Epub 2011 Jul 23.

31.

Nerve agent hydrolysis activity designed into a human drug metabolism enzyme.

Hemmert AC, Otto TC, Chica RA, Wierdl M, Edwards JS, Lewis SM, Edwards CC, Tsurkan L, Cadieux CL, Kasten SA, Cashman JR, Mayo SL, Potter PM, Cerasoli DM, Redinbo MR.

PLoS One. 2011 Mar 18;6(3):e17441. doi: 10.1371/journal.pone.0017441. Erratum in: PLoS One. 2012;7(1). doi:10.1371/annotation/c5953f27-95f8-4a1b-a46c-639d90e182ac. Lewis, Steven L [corrected to Lewis, Steven M].

32.

Amidine-oximes: reactivators for organophosphate exposure.

Kalisiak J, Ralph EC, Zhang J, Cashman JR.

J Med Chem. 2011 May 12;54(9):3319-30. doi: 10.1021/jm200054r. Epub 2011 Apr 11.

PMID:
21438612
33.

Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood.

Shimizu M, Denton T, Kozono M, Cashman JR, Leeder JS, Yamazaki H.

Br J Clin Pharmacol. 2011 Apr;71(4):585-91. doi: 10.1111/j.1365-2125.2010.03876.x.

34.

Flavin-containing monooxygenase mRNA levels are up-regulated in als brain areas in SOD1-mutant mice.

Gagliardi S, Ogliari P, Davin A, Corato M, Cova E, Abel K, Cashman JR, Ceroni M, Cereda C.

Neurotox Res. 2011 Aug;20(2):150-8. doi: 10.1007/s12640-010-9230-y. Epub 2010 Nov 17.

PMID:
21082301
35.

Inhibition of Bfl-1 with N-aryl maleimides.

Cashman JR, MacDonald M, Ghirmai S, Okolotowicz KJ, Sergienko E, Brown B, Garcia X, Zhai D, Dahl R, Reed JC.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6560-4. doi: 10.1016/j.bmcl.2010.09.046. Epub 2010 Sep 21.

36.

Characterization of human flavin-containing monooxygenase (FMO) 3 and FMO5 expressed as maltose-binding protein fusions.

Reddy RR, Ralph EC, Motika MS, Zhang J, Cashman JR.

Drug Metab Dispos. 2010 Dec;38(12):2239-45. doi: 10.1124/dmd.110.033639. Epub 2010 Sep 1.

37.

Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.

Peddibhotla S, Shi R, Khan P, Smith LH, Mangravita-Novo A, Vicchiarelli M, Su Y, Okolotowicz KJ, Cashman JR, Reed JC, Roth GP.

J Med Chem. 2010 Jun 24;53(12):4793-7. doi: 10.1021/jm1000248.

38.

SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis.

Gagliardi S, Cova E, Davin A, Guareschi S, Abel K, Alvisi E, Laforenza U, Ghidoni R, Cashman JR, Ceroni M, Cereda C.

Neurobiol Dis. 2010 Aug;39(2):198-203. doi: 10.1016/j.nbd.2010.04.008. Epub 2010 Apr 23.

PMID:
20399857
39.

Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.

Okolotowicz KJ, Shi R, Zheng X, MacDonald M, Reed JC, Cashman JR.

Bioorg Med Chem. 2010 Mar 1;18(5):1918-24. doi: 10.1016/j.bmc.2010.01.039. Epub 2010 Jan 25. Erratum in: Bioorg Med Chem. 2011 Feb 1;19(3):1367.

PMID:
20153655
40.

Direct detection of the hydrolysis of nerve agent model compounds using a fluorescent probe.

Zheng X, Okolotowicz K, Wang B, Macdonald M, Cashman JR, Zhang J.

Chem Biol Interact. 2010 Sep 6;187(1-3):330-4. doi: 10.1016/j.cbi.2010.01.027. Epub 2010 Jan 25.

41.

Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin.

Hemmert AC, Otto TC, Wierdl M, Edwards CC, Fleming CD, MacDonald M, Cashman JR, Potter PM, Cerasoli DM, Redinbo MR.

Mol Pharmacol. 2010 Apr;77(4):508-16. doi: 10.1124/mol.109.062356. Epub 2010 Jan 5.

42.

Design and synthesis of selective inhibitors of placental alkaline phosphatase.

Lanier M, Sergienko E, Simão AM, Su Y, Chung T, Millán JL, Cashman JR.

Bioorg Med Chem. 2010 Jan 15;18(2):573-9. doi: 10.1016/j.bmc.2009.12.012. Epub 2009 Dec 11.

43.

Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.

Cashman JR, Ghirmai S.

Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. doi: 10.1016/j.bmc.2009.08.025. Epub 2009 Aug 20.

PMID:
19740668
44.

Nerve agent analogues that produce authentic soman, sarin, tabun, and cyclohexyl methylphosphonate-modified human butyrylcholinesterase.

Gilley C, MacDonald M, Nachon F, Schopfer LM, Zhang J, Cashman JR, Lockridge O.

Chem Res Toxicol. 2009 Oct;22(10):1680-8. doi: 10.1021/tx900090m.

45.

Chemical synthesis of two series of nerve agent model compounds and their stereoselective interaction with human acetylcholinesterase and human butyrylcholinesterase.

Barakat NH, Zheng X, Gilley CB, MacDonald M, Okolotowicz K, Cashman JR, Vyas S, Beck JM, Hadad CM, Zhang J.

Chem Res Toxicol. 2009 Oct;22(10):1669-79. doi: 10.1021/tx900096j.

46.

Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.

Ghirmai S, Azar MR, Cashman JR.

Bioorg Med Chem. 2009 Sep 15;17(18):6671-81. doi: 10.1016/j.bmc.2009.07.069. Epub 2009 Aug 6.

47.

Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine.

Wee S, Orio L, Ghirmai S, Cashman JR, Koob GF.

Psychopharmacology (Berl). 2009 Sep;205(4):565-75. doi: 10.1007/s00213-009-1563-y. Epub 2009 May 30.

48.
49.

Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Motika MS, Zhang J, Zheng X, Riedler K, Cashman JR.

Mol Genet Metab. 2009 Jun;97(2):128-35. doi: 10.1016/j.ymgme.2009.02.006. Epub 2009 Feb 27.

50.

Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Cashman JR, Voelker T, Zhang HT, O'Donnell JM.

J Med Chem. 2009 Mar 26;52(6):1530-9. doi: 10.1021/jm8010993.

Supplemental Content

Loading ...
Support Center